Stocks in Focus : LookSmart, Ltd. (NASDAQ:LOOK), SandRidge Energy, Inc. (NYSE:SD), Apple Inc. (NASDAQ:AAPL), Montage Technology Group Limited (NASDAQ:MONT), ImmunoGen, Inc. (NASDAQ:IMGN)

LookSmart, Ltd. (NASDAQ:LOOK) gave back some of the gains it accumulated earlier when speculators moved in the stock following Facebook Inc (FB)’s launch of Atlas. The stock declined 10.2% to $2.20 Tuesday. Facebook announced the launching of Atlas, an online marketing service that allows brand to achieve targeted ads on the Web and mobile platforms. The move led to speculations that LOOK and other companies … Continue reading Stocks in Focus : LookSmart, Ltd. (NASDAQ:LOOK), SandRidge Energy, Inc. (NYSE:SD), Apple Inc. (NASDAQ:AAPL), Montage Technology Group Limited (NASDAQ:MONT), ImmunoGen, Inc. (NASDAQ:IMGN)

5 Stocks Under Wall Street’s Radar : Alibaba Group (NYSE:BABA), JD.com, Inc. (NASDAQ:JD), ImmunoGen (NASDAQ:IMGN), Oracle Corporation (NYSE:ORCL), CCA Industries Inc. (NYSEMKT:CAW),

Citi announced that Alibaba Group Holding Ltd (NYSE:BABA) has appointed Citi’s Issuer Services business, acting through Citibank, N.A., as the depositary bank for its American Depositary Receipt (“ADR”) program. Alibaba Group’s ADRs, which began trading on September 19, 2014, represent the largest Depositary Receipt program in initial public offering market history. Alibaba Group Holding Ltd (NYSE:BABA) belongs to Services sector. On last trading day company … Continue reading 5 Stocks Under Wall Street’s Radar : Alibaba Group (NYSE:BABA), JD.com, Inc. (NASDAQ:JD), ImmunoGen (NASDAQ:IMGN), Oracle Corporation (NYSE:ORCL), CCA Industries Inc. (NYSEMKT:CAW),

Hot Alert : ImmunoGen (NASDAQ:IMGN), Walt Disney Company (NYSE:DIS), Shanda Games Limited (NASDAQ:GAME), EQT Midstream Partners, LP (NYSE:EQM), Northeast Bancorp (NASDAQ:NBN)

The National Institute of Health and Care Excellence (NICE) – the drugs advisory body to the National Health Service (NHS) in the UK – has criticized Roche Holding Ltd. (ADR) (RHHBY) over its refusal to cut prices for Kadcyla, which is used to treat severe cases of breast cancer. Kadcyla is approved to treat HER2-positive breast cancer that has spread to other parts of the … Continue reading Hot Alert : ImmunoGen (NASDAQ:IMGN), Walt Disney Company (NYSE:DIS), Shanda Games Limited (NASDAQ:GAME), EQT Midstream Partners, LP (NYSE:EQM), Northeast Bancorp (NASDAQ:NBN)

Hot Movers: Novartis AG (NYSE:NVS), IMAX Corporation (NYSE:IMAX), ImmunoGen (NASDAQ:IMGN), bluebird bio (NASDAQ:BLUE), Randgold Resources (NASDAQ:GOLD)

Novartis AG (ADR) (NYSE:NVS) announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults from 10 years through 25 years of age. Novartis AG … Continue reading Hot Movers: Novartis AG (NYSE:NVS), IMAX Corporation (NYSE:IMAX), ImmunoGen (NASDAQ:IMGN), bluebird bio (NASDAQ:BLUE), Randgold Resources (NASDAQ:GOLD)

Losers At Healthcare: Synageva BioPharma (NASDAQ:GEVA), Auspex Pharmaceuticals (NASDAQ:ASPX), ImmunoGen (NASDAQ:IMGN), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Synageva BioPharma Corp (NASDAQ:GEVA) last released its earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.90 EPS for the current fiscal year. Synageva BioPharma Corp (NASDAQ:GEVA)stock performance was 5.87% in last session and finished the day at $ 85.40. Traded … Continue reading Losers At Healthcare: Synageva BioPharma (NASDAQ:GEVA), Auspex Pharmaceuticals (NASDAQ:ASPX), ImmunoGen (NASDAQ:IMGN), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Biotech Unusual Volume: Zalicus Inc (NASDAQ:ZLCS), ImmunoGen (NASDAQ:IMGN), Transition Therapeutics (NASDAQ:TTHI), Lpath (NASDAQ:LPTN)

Zalicus Inc (NASDAQ:ZLCS) will merge with Epirus Biopharmaceuticals in an all-stock transaction. Zalicus will be known as Epirus and will operate under the latter company’s management team led by Amit Munshi as president and CEO. Current Zalicus Inc (NASDAQ:ZLCS) stockholders will own approximately 19% of the company. The merger will create a publicly-traded company listed on the NASDAQ. Zalicus Inc (NASDAQ:ZLCS) stock performance was 31.07% … Continue reading Biotech Unusual Volume: Zalicus Inc (NASDAQ:ZLCS), ImmunoGen (NASDAQ:IMGN), Transition Therapeutics (NASDAQ:TTHI), Lpath (NASDAQ:LPTN)